This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In today’s food and beverage industry, protein enrichment has become a pivotal trend, driven by consumers’ growing awareness of health and nutrition. High-protein products are in demand across various categories, from bakery and dairy (alternatives) to sports nutrition and savoury foods.
On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. This is important due to the UK’s currently limited short-scale manufacturing capacity.
Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.
Xenetic Biosciences and Catalent Pharma Solutions have signed an agreement for the cGMP manufacturing of the Xenetic’s recombinant protein, Human DNase I. The post Xenetic Biosciences and Catalent sign deal for cGMP manufacturing appeared first on Pharmaceutical Technology.
Cytovance Biologics has entered a collaboration deal with Phenotypeca to enhance the development of saccharomyces cerevisiae strain for biopharmaceutical manufacturing. According to the company, saccharomyces cerevisiae is broadly utilised in the biopharmaceutical industry for safe therapeutic proteins and other biologics production.
The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel. The regulatory approval represents the completion of the Cytogam technology transfer process from CSL Behring, its previous manufacturer.
API peptides and proteins-based drugs have gained much attention in the past decade. The increasing demand for API peptide products is in turn increasing the demand for peptide API manufacturers who also offer contract marketing services. Discover the top API protein and peptide companies in contract marketing.
WuXi Biologics and InflaRx have entered a manufacturing partnership for advancing Gohibic (vilobelimab) to treat certain critically ill Covid-19 patients. Under the collaboration, WuXi Biologics will be responsible for providing cGMP manufacturing of Gohibic.
One such fusion beverage is high-protein iced tea – a functional, refreshing beverage that has the potential to be the next big beverage trend. As an ingredient, whey protein comes with some challenges. It’s not as simple as adding protein powder to iced tea, otherwise everyone would be doing it. This is where iced tea comes in.
Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.
Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.
The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon.
Its platform delivers ingredient solutions for both chefs and food manufacturers, all while diverting tons of waste. In 2025, the company faced US import tariffs on goods from China where it manufactures its products prompting adjustments to its supply chain to continue sourcing key regional ingredients.
In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. If it exercises its option, Novartis will assume responsibility for future development, manufacturing and global commercialisation of therapeutics arising from the alliance.
In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. For 2025, Smithfield projects an adjusted operating profit of up to $1.3
For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes.
Novo will pay $200 million to gain control of the proteinmanufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. Using the advanced manufacturing platform of NRC, these vaccine antigens are expected to be quickly deployable in next-generation vaccine formulations.
By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.
Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. First, a novel approach was used that didn’t require traditional vaccine production in cell cultures or eggs. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.
Credit: Meditech Gloves Cranfield University researchers in partnership with Meditech Gloves, one of the leading manufacturers of high-quality examination and surgical gloves, have shown how energy savings can be made with the development of more sustainable, biodegradable, protein-free, natural rubber gloves.
Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. This left the country without production capabilities for large-scale manufacturing of COVID-19 vaccines.
With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve.
The company has presently attained steady manufacturing of several innovative vaccines and set up a supply chain worldwide to increase accessibility to quality vaccine products for people globally.
Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. Regulators in Japan have granted approval for the manufacturing plant of Kite in El Segundo, California, US, to produce Yescarta for the Japanese market.
Scientists have known for decades that biological cells manufacture tiny, round structures called extracellular vesicles. However, their pivotal roles […].
Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicyclic peptides feature amino acids that can be manufactured synthetically.
The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.
EQUII, a food tech startup renowned for its protein bread that focuses on high complete protein and low carbs, is expanding its product line. This new range, which debuted at Expo East last week, includes Plain and Multigrain protein bread, delivering consumers a blend of nutrition without compromising on flavor.
The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform. ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp.
Symvess is a one-time, single-use, acellular tissue-engineered vessel (ATEV) composed of human extracellular matrix proteins. Manufactured using vascular smooth muscle cells derived from human aortic tissue, Symvess offers a novel solution for patients with traumatic vascular injuries.
The advantages of using circular RNAs—including increased durability, enhanced protein expression, and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.
According to Bioplan Associates, single-use bioprocessing technologies now dominate the pre-commercial manufacturing space. However, Alfa Laval states many companies have not been able to make the transition to ‘full-single-use’ when harvesting proteins due to the lack of a single-use disc-stack centrifuge.
A vaccine called Lymerix , then manufactured by SmithKline Beecham, was approved in the US in 1998 but was quickly withdrawn in 2002 due to insufficient custo mer demand. However, advances in research allowed for the identification of outer surface protein A (OspA) of the bacteria as a target for vaccines.
Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.
Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The expanded manufacturing and marketing approval was based on the data obtained from the Phase II trial, conducted in Australia and the US; a separate Phase II trial held in South Africa; and the UK-sponsored COV-BOOST trial.
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.
CDMO AGC Biologics will produce Tzield (teplizumab-mzwv), a recently-approved T1D treatment from Provention Bio, at its Seattle protein biologics manufacturing site.
The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026.
AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.
AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content